In conclusion, our findings reveal that HU pre-treatment in patients with CP-CML has no clinical cytoreductive benefit, and we demonstrate that any kind of therapy administered before a confirmed diagnosis of CML might change the amount of BCR::ABL1 expression levels (Figure 4). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.